机译:Ivosidenib或Enasidenib结合新诊断的AML患者的强烈化疗:1期研究
Mem Sloan Kettering Canc Ctr Dept Med 1275 York Ave New York NY 10021 USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Massachusetts Gen Hosp Dana Faber Harvard Canc Ctr Boston MA 02114 USA;
Ohio State Univ Wexner Med Ctr Columbus OH USA;
Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;
Vanderbilt Univ Sch Med Vanderbilt Ingram Ctr Nashville TN 37212 USA;
City Hope Med Ctr Dept Hematol &
Hematopoiet Cell Transplantat Duarte CA USA;
Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;
Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;
Univ Calif Los Angeles Med Ctr Dept Med Los Angeles CA 90024 USA;
Univ Hosp Ulm Dept Internal Med 3 Ulm Germany;
Univ Colorado Sch Med Dept Med Aurora CO USA;
Hackensack Univ John Theurer Canc Ctr Med Ctr Hackensack NJ USA;
Univ Chicago Med Comprehens Canc Ctr Chicago IL USA;
Erasmus MC Dept Hematol Rotterdam Netherlands;
VUmc Canc Ctr Dept Hematol Amsterdam Netherlands;
Univ Texas Southwestern Med Ctr Dallas Dept Internal Med Dallas TX USA;
Mem Sloan Kettering Canc Ctr Dept Pathol 1275 York Ave New York NY 10021 USA;
Bristol Myers Squibb Summit NJ USA;
Celgene Int Boudry Switzerland;
Bristol Myers Squibb San Francisco CA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Agios Pharmaceut Inc Cambridge MA USA;
Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;
Mem Sloan Kettering Canc Ctr Dept Med 1275 York Ave New York NY 10021 USA;
机译:Ivosidenib或Enasidenib结合患有新诊断的AML的诱导和固结化疗,其具有IDH1或IDH2突变是安全的,有效的,导致MRD-负完全剩余释放
机译:两种方案的低剂量吉妥珠单抗奥佐米星作为诱导单一疗法的随机对照试验,用于在不考虑进行强力化疗的老年患者中新诊断的急性髓细胞性白血病。 EORTC和GIMEMA白血病组(AML-19)的II期研究
机译:两种方案的低剂量吉妥珠单抗奥佐米星作为诱导性单药治疗在不被认为是强化化疗候选药物的老年患者中的新诊断的急性髓细胞白血病的随机试验。 EORTC和GIMEMA白血病组(AML-19)的II期研究
机译:TeleMed-支持新诊断的1型糖尿病患者强化胰岛素治疗的远程信息处理系统:首次临床应用
机译:新诊断头颈癌患者接受明确放疗并伴或不伴化疗的症状,症状困扰,抑郁症状和不确定性
机译:两次低剂量Gemtuzumab ozogamicin的随机试验作为新诊断的急性髓细胞白血病对老年患者的诱导单一的疗法而不是考虑到密集化疗的候选人。 EITTC和Gimema白血病组的II期研究(AML-19)
机译:Ivosidenib或Enasidenib结合新诊断的AML患者的强烈化学疗法:1期研究
机译:新诊断癫痫患者的管理:文献的系统评价。证据报告/技术评估编号39。